Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Humalog ® (insulin lispro)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Humalog® (insulin lispro): Changing from other mealtime insulin products
Dose adjustment may be needed when transitioning from another insulin to insulin lispro.
Dose adjustment may be needed when transitioning from another insulin to IL-100.1
A change in dosage of insulin may be needed when there are changes in
type (regular/soluble, NPH/isophane, etc)
species (animal, human, human insulin analogue) and/or
method of manufacture (recombinant DNA versus animal-source insulin).2
For fast-acting insulins, any patient also on basal insulin must optimise dosage of both insulins to obtain glucose control across the whole day, particularly nocturnal/fasting glucose control.2
Transferring a patient with DM to another type or brand of insulin should be done under strict medical supervision.2
DM = diabetes mellitus
GC = glucose control
IL-100 = Humalog® (insulin lispro) 100 units/mL
Date of Last Review: 27 January 2020